Zejula

The year has been good for pharma and biotech companies, with earnings, drug approvals and M&A fueling strong buying in the space. Another multibillion-dollar deal was announced Monday. What Happened Large-cap biotech GlaxoSmithKline plc (NYSE: GSK) and TESARO Inc (NASDAQ: TSRO) announced a...

Morgan Stanley said in a note Tuesday it would be buyers of Clovis Oncology Inc (NASDAQ: CLVS) and TESARO Inc (NASDAQ: TSRO) ahead of the Lynparza label decision. AstraZeneca plc (ADR) (NYSE: AZN)'s Lynparza is a poly polymerase, or PARP, inhibitor indicated for use as a monotherapy in patients...

TESARO Inc (NASDAQ: TSRO) takeover rumors have been swirling around since September 2016, and Benzinga continues to hear M&A chatter Tuesday. The biopharmaceutical company has been a huge acquisition target, as biotech companies look to gain access to Zejula, an approved inhibitor to treat...